• Pentixapharm flagged over USD 1 billion in annual revenue potential for its [68Ga]Ga-PentixaFor PET/CT diagnostic in primary aldosteronism, contingent on approval.
• Market thesis centers on underdiagnosis in hypertension: primary aldosteronism estimated at 5%-10% of hypertensive patients, or about 6.5-7 million in the US.
• Strategy targets replacement of adrenal vein sampling with a non-invasive PET/CT workflow; broad radiopharmacy readiness cited as a low adoption barrier.
• FDA feedback cleared the Phase III PANDA study to proceed; trial to enroll about 270 patients with a planned US launch in 2030.
• Benchmark cited: US PSMA-PET diagnostics grew to roughly USD 1.5 billion in annual revenue for leading providers by 2024.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pentixapharm Holding AG published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2341872_en) on June 09, 2026, and is solely responsible for the information contained therein.